Biotech entity
All 1 tracked stories fall under one category: pharma. Citigroup is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. ResMed appears in 1 tracked Biotech story from July 10, 2026. The tracked stories average 2 original sources each.
Last mentioned: Aug 17, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Citigroup is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. ResMed appears in 1 tracked Biotech story from July 10, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 1 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ResMed. Shared-story counts are live from our verified record — not editorial picks.
Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Source: Ticker Report · Watch List News
ResMed is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
